Making Cell-Penetrating Peptides Smarter: Designs That Only Activate Inside Tumors

Tumor microenvironment-responsive CPP designs address the selectivity limitation through activation mechanisms triggered by tumor-specific conditions including low pH, overexpressed enzymes, hypoxia, elevated GSH, and ROS.

Comprehensive review article systematically categorizing TME-responsive CPP strategies by activation mechanism, covering single-stimulus, multi-stimulus, targeted, and reversibly activatable designs, plus their nanomedical applications.

CPPs could revolutionize drug delivery by ferrying therapeutics directly into cancer cells, but their lack of selectivity has prevented clinical use. TME-responsive activation solves this by keeping the CPP 'off' in healthy tissue and 'on' only inside tumors — potentially enabling a new generation of targeted cancer treatments with fewer side effects.

This review captures a field at an inflection point. After decades of promise but limited clinical progress, TME-responsive CPP designs represent the most credible path to bringing cell-penetrating peptides into clinical cancer therapy. The diversity of approaches — from pH-sensitive masks to enzyme-cleavable linkers — suggests multiple viable solutions may emerge for different tumor types.

Review article — most TME-responsive CPPs are still in preclinical development. Tumor microenvironment heterogeneity (differences between and within tumors) may limit consistent activation. Manufacturing complexity increases with responsive design elements. Few head-to-head comparisons exist between different activation strategies.